{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-026748","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2023-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.821756+00:00","generated_at":"2026-06-14T06:16:14.974372+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FibroGen's pamrevlumab fails Phase 3 DMD study in non-ambulatory patients; primary endpoint not met","bullets":["Phase 3 LELANTOS-1 study of pamrevlumab in non-ambulatory DMD patients did not meet primary endpoint (PUL 2.0 score at week 52).","Pamrevlumab was generally safe and well tolerated; most adverse events were mild or moderate.","Topline results from LELANTOS-2 Phase 3 study in ambulatory DMD patients expected in Q3 2023.","CEO Enrique Conterno expressed disappointment and thanked patients, caregivers, and investigators."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-026748","json":"https://secwatch.observer/filing/0000950170-23-026748.json","markdown":"https://secwatch.observer/filing/0000950170-23-026748.md","text":"https://secwatch.observer/filing/0000950170-23-026748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017023026748/0000950170-23-026748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017023026748/fgen-20230607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:16:14.974372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}